Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/
AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.
About Debiopharm Research & Manufacturing
Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit: www.debiopharm.com
Follow us on LinkedIn https://www.linkedin.com/company/debiopharminternational/
About Oncodesign Services
Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands.
More information on the website www.oncodesign-services.com
Follow us on LinkedIn https://www.linkedin.com/company/oncodesign/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424538240/en/
Contacts
Debiopharm Research & Manufacturing Contact:
Dawn Bonine – Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Oncodesign Services Contact:
Nathalie Dubois – Marketing Manager
comms@oncodesign-services.com
Tel.: +33 (0)3 80 78 82 60
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Named a 2025 Geo and Global AWS Partner Award Finalist8.12.2025 16:00:00 EET | Press release
Boomi™, the leader in AI-driven automation, today announced it is a finalist for a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Boomi is excited to announce it has been named a finalist for Rising Star Partner of the Year (Technology), which honors the top AWS Partner that has seen significant year-over-year growth in their Technology business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208700959/en/ Boomi Named a 2025 Geo and Global AWS Partner Award Finalist The Geography and Global AWS Partner Awards recognize a wide range of AWS Partners that have embraced specialization, innovation, and cooperation over the past year. Geo and Global AWS Partner Awards commend partners whose business models continue to evolve and thrive on AWS as they support their customers.
iFIT and F45 Training Announce Global Partnership to Bridge Digital and Studio Fitness8.12.2025 16:00:00 EET | Press release
iFIT, a global leader in connected fitness, content, and equipment, and F45 Training, a leading global fitness community and franchise, today announced a new global partnership that will redefine the member experience by seamlessly integrating at-home digital training with in-studio community fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208170773/en/ Launching December 8, the collaboration combines F45 Training’s world-class, high-intensity functional training methodology with iFIT’s immersive workout production capabilities and expansive global platform. Integrated Fitness Collaboration This strategic partnership is built on two key pillars designed to drive engagement for both platforms: Premium Digital Content Access: iFIT will license and feature a curated collection of F45 Training’s signature functional, at-home workouts on its global streaming platform. This immediately brings F45’s acclaimed, results-dr
PHOTRON LIMITED Announces Acquisition of AOS Technologies AG8.12.2025 16:00:00 EET | Press release
PHOTRON LIMITED, a global leader in high-speed and scientific imaging solutions, today announced its acquisition of AOS Technologies AG, a Swiss-based designer and manufacturer of advanced high-speed imaging systems serving automotive, aerospace, industrial, and defense markets. Founded in 2002, AOS Technologies has earned worldwide recognition for its engineering innovation, rugged imaging platforms, and application expertise. The acquisition strengthens PHOTRON’s global strategy to expand technical capabilities, accelerate innovation, and grow its presence across high-performance imaging markets. “AOS Technologies brings engineering depth and a strong product portfolio that is complementary to PHOTRON’s long-term vision,” said Takashi Takimizu, President of PHOTRON LIMITED. “As PHOTRON continues to strengthen its growth strategy through targeted M&A activity and strategic business alliances, this partnership reflects our commitment to building a broader, more innovative global imagin
Guidewire Olos Release Powers Intelligent Pricing, Drives Faster Rate Changes, and Enhances Workers’ Compensation Performance8.12.2025 15:55:00 EET | Press release
Guidewire (NYSE: GWRE) today announced Olos, its latest release, designed to help P&C insurers modernize their pricing strategies, accelerate rate changes, optimize underwriting processes, and strengthen workers’ compensation performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208759369/en/ Faster, Smarter Pricing and Rating with Guidewire PricingCenter Guidewire PricingCenter unifies the entire pricing and rating lifecycle, eliminating manual handoffs across actuarial, pricing, and IT teams. The platform supports dynamic price modeling and impact analysis, AI-assisted pricing insights, as well as seamless integration with other Guidewire applications and services, enabling faster rate changes and greater agility. “PricingCenter gives insurers a single platform to model, test, and deploy pricing changes with speed and confidence,” said Dawid Kopczyk, Senior Director, Pricing and Rating, Guidewire. “By unifying wor
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 15:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne. “Long-term data are the gold standard in CLL, and BRUKINSA continues to deliver the high levels of durable progression-free and overall survival that patients and physicians should demand from a BTK inhibitor. BGB-16673, the most advanced BTK degrader in the clinic with over 800 patients dosed to date, potentially repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom